Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
November 12, 2025
-
BUSINESS J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
-
REGULATORY Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
November 11, 2025
-
REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
-
REGULATORY Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
-
COMMENTARY Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
-
BUSINESS MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
-
REGULATORY MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
-
BUSINESS Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
-
REGULATORY Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
-
REGULATORY MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
-
REGULATORY Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
-
BUSINESS Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
-
BUSINESS Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
-
BUSINESS Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
-
BUSINESS Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
-
BUSINESS Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
-
REGULATORY LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
-
REGULATORY Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
-
REGULATORY Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…